局限晚期前列腺癌伴区域淋巴结转移:EBRT联合或不联合HDR近距离放疗 boost 的多中心回顾性倾向评分匹配分析
该多中心回顾性研究纳入360例临床淋巴结阳性前列腺癌患者,均接受EBRT和ADT,约三分之一联合HDR近距离放疗 boost。倾向评分匹配后两组无转移生存无显著差异,但ISUP 4-5亚组中 boost 组无转移生存显著改善,且晚期≥2级胃肠道毒性更低。
要点
- 总体人群倾向评分匹配后,BT boost 未显著改善无转移生存。
- ISUP 4-5亚组中,BT boost 组中位无转移生存显著优于无 boost 组。
- BT boost 组晚期≥2级胃肠道毒性发生率显著更低。
核心结论
- 在未选择的临床淋巴结阳性前列腺癌患者中,BT boost 未与更好的结局相关。
- 亚组分析提示 ISUP 4-5 患者中 BT boost 与改善的结局相关,且 BT boost 组中度或更差胃肠道毒性更低。
研究设计与样本
- 多中心回顾性研究,纳入2008至2023年间8个中心治疗的360例临床淋巴结阳性前列腺癌患者。
- 所有患者接受EBRT(100%)和ADT(99.5%),约三分之一(33.6%)接受前列腺HDR-BT boost。
- 主要终点为无转移生存,采用倾向评分匹配、log-rank检验和多变量Cox回归分析。
主要发现
- 倾向评分匹配分析中,BT boost 组与无 boost 组无转移生存无显著差异(中位84.6 vs. 77.7个月;p=0.6)。
- ISUP 4-5亚组(n=139)中,BT boost 组无转移生存显著改善(中位84.6 vs. 48.9个月;p=0.007)。
- 多变量分析中,校正ISUP后BT boost 为无转移生存的独立预后因素(HR 0.63;95%CI 0.4-0.98;p=0.041)。
- BT boost 组晚期≥2级胃肠道毒性发生率显著更低(2.5% vs. 10.9%,p=0.02)。
关键数值与推荐
- 无转移生存:BT boost 组中位84.6个月 vs. 无 boost 组77.7个月(倾向评分匹配分析,p=0.6)。
- ISUP 4-5亚组无转移生存:BT boost 组中位84.6个月 vs. 无 boost 组48.9个月(p=0.007)。
- 多变量分析:BT boost 的HR 0.63(95%CI 0.4-0.98;p=0.041)。
- 晚期≥2级胃肠道毒性:BT boost 组2.5% vs. 无 boost 组10.9%(p=0.02)。
临床怎么用
- 对于临床淋巴结阳性前列腺癌接受ADT和EBRT的患者,BT boost 可作为ISUP 4-5患者的个体化选择。
- BT boost 与更低的晚期≥2级胃肠道毒性相关,支持其作为剂量递增方式的可行性。
局限性
- 回顾性研究设计,存在选择偏倚。
- BT boost 组样本量较小(约三分之一病例)。
- 结果需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients treated for clinically node-positive prostate cancer (PCa) are at high risk of recurrence. Local radiation dose escalation with brachytherapy (BT) has been shown to improve outcomes in advanced localised disease, but evidence is lacking for patients with pelvic lymph node metastases. METHODS: We retrospectively collected data on patients treated for clinically node-positive PCa with definitive external beam radiation therapy (EBRT) and androgen-deprivation therapy (ADT), with or without dose-escalation to the prostate using high-dose-rate (HDR)-BT. The primary endpoint was metastasis-free survival (MFS). Toxicity was evaluated according to the RTOG/EORTC criteria. Survival analysis included propensity-score matching followed by log-rank tests, and multivariable Cox regression models. KEY FINDINGS AND LIMITATIONS: We included 360 patients treated at eight centers between 2008 and 2023 with EBRT (100 %) and ADT (99.5 %), with a BT-boost to the prostate in approximately one third of the cases (33.6 %). No significant differences in MFS were observed between groups in a propensity-score matching analysis (median 84.6 vs. 77.7 months; p = 0.6); however, a subgroup analysis of patients with International Society of Urological Pathology (ISUP) 4-5 PCa (n = 139) indicated significantly improved MFS in those who received BT-boost (median 84.6 vs. 48.9 months; p = 0.007). BT-boost was an independent prognostic factor for MFS in a multivariable analysis accounting for ISUP (hazard ratio: 0.63; 95 % confidence interval: 0.4-0.98; p = 0.041). The incidence of late grade ≥ 2 gastrointestinal (GI) toxicity was significantly lower in patients treated with BT-boost (2.5 % vs. 10.9 %, p = 0.02). CONCLUSION: BT-boost was not associated with improved outcomes in unselected patients treated with ADT and EBRT for clinically node-positive prostate cancer. However, subset analysis indicated that BT-boost was associated with improved outcomes in patients with ISUP grade 4-5 disease, and patients treated with BT-boost had lower rates of moderate or worse GI toxicity. Prospective studies are necessary to validate these findings.
引用
- Bilski M, Lelek P, Stankiewicz M, et al. MUlticentre REtrospective comparison of definitive EBRT with or without HDR BRAchytherapy boost in patients with locally-advanced prostate cancer and regional lymph NOde metastases (MUREBRANO) - A propensity score matched analysis. Radiother Oncol. 2025. PMID: 40882818. doi:10.1016/j.radonc.2025.111112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。